Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4):486–495
Article
CAS
PubMed
Google Scholar
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20
Article
CAS
PubMed
Google Scholar
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M et al (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209
Article
CAS
PubMed
Google Scholar
Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD et al (2021a) Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 48(9):2978–2989
Article
CAS
PubMed
PubMed Central
Google Scholar
Alberts I, Mingels C, Zacho HD, Lanz S, Schöder H, Rominger A et al. Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. Eur J Nucl Med Mol Imaging. 2021b.
Ali A, Hoyle AP, Parker CC, Brawley CD, Cook A, Amos C et al (2020) The automated bone scan index as a predictor of response to prostate radiotherapy in men with newly diagnosed metastatic prostate cancer: an exploratory analysis of STAMPEDE’s “M1|RT comparison.” Eur Urol Oncol 3(4):412–419
Article
PubMed
PubMed Central
Google Scholar
Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A et al (2018) Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(7):944–951
Article
PubMed
PubMed Central
Google Scholar
Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W (2016) Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET/CT. J Nucl Med 57(Supplement 3):55S-60S
Article
CAS
PubMed
Google Scholar
Bortot DC, Amorim BJ, Oki GC, Gapski SB, Santos AO, Lima MCL et al (2012) 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 39(11):1730–1736
Article
PubMed
Google Scholar
Buenrostro D, Mulcrone PL, Owens P, Sterling JA (2016) The bone microenvironment: a fertile soil for tumor growth. Curr Osteoporos Rep 14(4):151–158
Article
PubMed
PubMed Central
Google Scholar
Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286–1294
Article
CAS
PubMed
PubMed Central
Google Scholar
Cook GJR, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging 4(6):439–447
Article
PubMed
PubMed Central
Google Scholar
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642
Article
PubMed
Google Scholar
Diao Wei JZ, Liao X (2019) Recent advances in prostate-specific membrane antigen-based radiopharmaceuticals. Curr Top Med Chem 19(1):33–56
Article
CAS
PubMed
Google Scholar
Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C et al (2019) 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29(3):1221–1230
Article
PubMed
Google Scholar
Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23(4):688–697
Article
CAS
PubMed
Google Scholar
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B et al (2015) Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56(5):668–674
Article
PubMed
Google Scholar
Fonager RF, Zacho HD, Langkilde NC, Fledelius J, Ejlersen JA, Haarmark C et al (2017) Diagnostic test accuracy study of (18)F-sodium fluoride PET/CT, (99m)Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. Am J Nucl Med Mol Imaging 7(5):218–227
PubMed
PubMed Central
Google Scholar
Fornetti J, Welm AL, Stewart SA (2018) Understanding the bone in cancer metastasis. J Bone Miner Res 33(12):2099–2113
Article
CAS
PubMed
Google Scholar
Fourquet A, Rosenberg A, Mena E, Shih JJ, Turkbey B, Blain M et al. A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. J Nucl Med. 2021:jnumed.121.262371.
Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V et al (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68(2):325–334
Article
PubMed
Google Scholar
Gareen IF, Hillner BE, Hanna L, Makineni R, Duan F, Shields AF et al (2018) Hospice admission and survival after (18)F-fluoride PET performed for evaluation of osseous metastatic disease in the national oncologic PET registry. J Nucl Med 59(3):427–433
Article
CAS
PubMed
PubMed Central
Google Scholar
Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y et al (2018) A prospective comparison of 18f-sodium fluoride PET/CT and PSMA-targeted 18F-DCFBC PET/CT in metastatic prostate cancer. J Nucl Med 59(11):1665–1671
Article
CAS
PubMed
PubMed Central
Google Scholar
Hernandez RK, Wade SW, Reich A, Pirolli M, Liede A, Lyman GH (2018) Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 18(1):44
Article
PubMed
PubMed Central
Google Scholar
Herrera FGTT, Berthold DR (2015) Bone cancer: Primary bone cancers and metastases, 2nd edn. Elsevier, San Diego
Google Scholar
Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM et al (2018) Intended versus inferred treatment after (18)F-fluoride PET performed for evaluation of osseous metastatic disease in the national oncologic PET registry. J Nucl Med 59(3):421–426
Article
CAS
PubMed
PubMed Central
Google Scholar
Iagaru A, Mittra E, Dick DW, Gambhir SS (2012) Prospective evaluation of 99mTc MDP scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 14(2):252–259
Article
PubMed
Google Scholar
Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S et al (2016) Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 55(1):59–67
Article
PubMed
Google Scholar
Janssen J-C, Meißner S, Woythal N, Prasad V, Brenner W, Diederichs G et al (2018) Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: additional value of morphologic information from low dose CT. Eur Radiol 28(2):610–619
Article
PubMed
Google Scholar
Langsteger W, Rezaee A, Pirich C, Beheshti M (2016) 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med 46(6):491–501
Article
PubMed
Google Scholar
Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E et al (2018) 68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 16(5):392–401
Article
PubMed
Google Scholar
Lindström E, Velikyan I, Regula N, Alhuseinalkhudhur A, Sundin A, Sörensen J et al (2019) Regularized reconstruction of digital time-of-flight (68)Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients. Theranostics 9(12):3476–3484
Article
PubMed
PubMed Central
Google Scholar
Madsen C, Østergren P, Haarmark C (2020) The value of 68Ga-PSMA PET/CT following equivocal 18F-NaF PET/CT in prostate cancer patients. Diagnostics 10(6):352
Article
CAS
PubMed Central
Google Scholar
McGeorge S, Kwok M, Jiang A, Emmett L, Pattison DA, Thomas PA et al (2021) Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review. Adv Urol 2021:1544208
Article
PubMed
PubMed Central
Google Scholar
Miyoshi Y, Uemura K, Kawahara T, Yoneyama S, Hattori Y, Teranishi J-I et al (2017) Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Clin Genitourin Cancer 15(4):472–478
Article
PubMed
Google Scholar
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629
Article
PubMed
Google Scholar
Nakajima K, Edenbrandt L, Mizokami A (2017) Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol 24(9):668–673
Article
PubMed
Google Scholar
Poulsen MH, Petersen H, Høilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J et al (2014) Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT. BJU Int 114(6):818–823
Article
CAS
PubMed
Google Scholar
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M et al (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43(12):2114–2121
Article
CAS
PubMed
Google Scholar
Quiroz-Munoz M, Izadmehr S, Arumugam D, Wong B, Kirschenbaum A, Levine AC (2019) Mechanisms of osteoblastic bone metastasis in prostate cancer: role of prostatic acid phosphatase. J Endocr Soc 3(3):655–664
Article
CAS
PubMed
PubMed Central
Google Scholar
Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol 62(1):78–84
Article
PubMed
PubMed Central
Google Scholar
Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C et al (2018) Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging 45(11):1873–1883
Article
CAS
PubMed
Google Scholar
Wang M, Xia F, Wei Y, Wei X (2020) Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res 8:30
Article
CAS
PubMed
PubMed Central
Google Scholar
Wibmer AG, Burger IA, Sala E, Hricak H, Weber WA, Vargas HA (2016) Molecular imaging of prostate cancer. Radiographics 36(1):142–159
Article
PubMed
Google Scholar
Wiyanto J, Shintawati R, Darmawan B, Hidayat B, Kartamihardja AHS (2017) Automated bone scan index as predictors of survival in prostate cancer. World J Nucl Med 16(4):266–270
Article
PubMed
PubMed Central
Google Scholar
Wondergem M, van der Zant FM, van der Ploeg T, Knol RJJ (2013) A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 34(10):935–945
Article
CAS
PubMed
Google Scholar
Yang HL, Liu T, Wang XM, Xu Y, Deng SM (2011) Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21(12):2604–2617
Article
PubMed
Google Scholar
Zacho HD, Nielsen JB, Dettmann K, Haberkorn U, Langkilde NC, Jensen JB et al (2018a) 68Ga-PSMA PET/CT in patients with biochemical recurrence of prostate cancer: a prospective, 2-center study. Clin Nucl Med 43(8):579–585
Article
PubMed
Google Scholar
Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K et al (2018b) Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45(11):1884–1897
Article
CAS
PubMed
Google Scholar
Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ (2020) Added value of (68)Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous (99m)Tc bone scintigraphy. EJNMMI Res 10(1):31
Article
PubMed
PubMed Central
Google Scholar